#USA #Bellevue #Circulate Health #Viome #Plasma Exchange

Viome's Acquisition of Circulate Health

In a landmark move within the preventive health sector, Viome Life Sciences has successfully acquired Circulate Health, a trailblazer in therapeutic plasma exchange (TPE). This strategic acquisition aims to create a seamless connection between early diagnostics, precision nutrition, and effective treatment protocols, thereby revolutionizing how health interventions are delivered.

The merging of Viome and Circulate Health provides physicians with an integrated platform to assess biological insights and implement tailored health interventions. With a robust clinical network of over 200 clinics nationwide, this partnership enhances the ability to address healthspan and chronic diseases through innovative solutions.

Naveen Jain, the visionary founder of Viome, emphasized the importance of this acquisition, stating, "We don't accept that declining health is inevitable. The future of medicine is about measurable improvements in health, year after year." This reflects Viome's commitment to not just diagnosing health issues but actively enabling precise interventions for better health outcomes.

Viome has consistently focused on translating diagnostic insights into actionable health strategies. However, the scope of available responses has historically been narrow. This is set to change as advancements in scientific understanding of biological aging and overall health emerges. The integration of Circulate's TPE protocols offers a significant enhancement to the array of tools clinicians can utilize in fostering patient health improvements.

Circulate Health’s network employs trained nurses to administer TPE in a controlled environment. This clinical approach, guided by physicians, ensures that the plasma exchange therapies adhere to established protocols. With Viome’s diagnostics layer, clinicians can implement precision health tactics more effectively, shifting from episodic treatment to long-term measurable health outcomes.

Dr. Brad Younggren, co-founder and CEO of Circulate Health, will take on the role of President within Viome’s new clinical group, Viome PRO. He remarked on the current moment in longevity medicine, saying, "We can measure more about human biology than ever before... Precision plasma exchange alongside Viome's capabilities offers a novel approach to practicing longevity medicine." This collaboration aims to broaden how health professionals can leverage insights from biological data.

Therapeutic plasma exchange has been a standard medical practice for over five decades and has been used to treat various autoimmune and neurological disorders. Circulate Health is at the forefront of applying this treatment modality for longevity purposes. Their precise clinical protocols have contributed significantly to the body of research in this arena, including a recent study published in the Journal of Clinical Apheresis. This research indicated that Circulate Health’s procedures helped reduce circulating levels of microplastics in patients' blood significantly.

Moreover, earlier findings published in Aging Cell highlighted that the application of Circulate’s plasma exchange protocol was associated with an average reduction of 2.6 years in biological age, based on a range of molecular biomarkers. These findings underscore the shared mission of both Viome and Circulate to drive scientific knowledge through rigorous and impactful clinical research.

Viome's long-term vision is to create a comprehensive precision longevity platform that unifies diagnostics, tailored interventions, and healthcare delivery. This enables the system to evolve in response to emerging tests, therapies, and innovations, fostering a more interconnected approach to preventive health that thrives on the holistic integration of all components.

About Viome Life Sciences

Founded in 2016, Viome Life Sciences aims to make illnesses optional by leveraging advanced molecular technology to predict and prevent chronic diseases, cancer, and aging. Their proprietary RNA sequencing technology, exclusively licensed from Los Alamos National Laboratory, allows for non-invasive early detection of high-mortality cancers and chronic diseases. By combining diagnostics with personal interventions and robust clinical delivery, Viome is committed to reshaping the future of healthcare for individuals seeking better health across their lifespan.